and I don't think there's a way to swap libraries. In the end, for my work notes, I had actually decided to stick with BBEdit, mostly because I don't want to contaminate my fiction writing environment in Ulysses with work notes. I guess I need a bit more organization than Bear, I do like folders. This is what led me to download Bear and try it out, although I have not comitted to it. ![]() This was awesome in Voodoopad and I still miss it. Tags are also segregated from the body of the note, which has pluses and minuses. Bear's implementation is better than Ulysses's in that in the latter you have to set up a smart group to find your certain tags. Bear and Ulysses are to my mind acceptable in this regard. Ulysses is my idea of beauty in this area though, and being able to choose any font on my hard drive is a plus. Other than that though, it looks pretty good. Bear loses a point here because I don't happen to like seeing a goofy drawing of a bear when I don't have a note selected. Most people using a Mac probably care a little more about how their stuff looks I guess. The iOS Mac OS integration of Ulysses is unbeatable. I haven't downloaded the iOS Bear app but I assume it works as well as the Mac app. Bear gets a big boost here, notes are highly legible. I only need a little bit of structure, so I could get away with like, four different markdown entities and be happy, but I'm particular about formatting, because looking at a mass of grey 13 point Consolas in BBEdit is more cognitive load. ![]() I'm still bummed about VoodooPad being semi-abandoned. Ulysses gets a boost here, as does Bear, because I feel like a subscription model is added insurance that the software will not be abandoned. As you mention, only text files can be relied on to still work the same way, five or fifteen years from now. For non-fiction related notes, I use a variety of things, mostly BBEdit and sometimes Vim, in markdown format (the vimwiki plugin is kind of nice). I do have some text files in a DropBox folder that are also imported into Ulysses. I have toyed around with Notational Velocity, and use Ulysses for fiction writing all the time, although the I use the native, iCloud library for the most part. Updating the systematic review by addition of the present result suggests a 12% relative survival benefit with the addition of neoadjuvant chemotherapy (1507 patients, HR 0.88, 95% CI 0.76-1.01, p=0.07), equivalent to an absolute improvement in survival of 5% at 5 yearsĪlthough there was no evidence of a difference in overall survival with neo-adjuvant chemotherapy, the result is statistically consistent with previous trials, and therefore adds considerable weight to the current evidence.I'm struggling with this again as well. However, there was no evidence of a benefit in terms of overall survival (hazard ratio 1.02, 95% CI 0.80-1.31, p=0.86). Post-operative complications were not increased in the CT-S group, and no impairment of quality of life was observed. Neo-adjuvant chemotherapy was feasible (75% of patients received all three cycles of chemotherapy), resulted in a good response rate (49% ) and down-staging in 31% (25%-37%) of patients, and did not alter the type or completeness of the surgery (lobectomy: S: 56%, CT-S: 60%, complete resection: S: 80%, CT-S: 82%). Most (61%) were clinical stage I, with 31% stage II, and 7% stage III. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN25582437.ĥ19 patients were randomised (S: 261, CT-S: 258) from 70 centres in the UK, Netherlands, Germany, and Belgium. The primary outcome measure was overall survival, which was analysed on an intention-to-treat basis. Before randomisation, clinicians chose the chemotherapy that would be given from a list of six standard regimens. Patients were randomised to receive either surgery alone (S), or three cycles of platinum-based chemotherapy followed by surgery (CT-S). In the 1990s, much interest was generated from two small trials that reported striking results with neo-adjuvant chemotherapy, and therefore our intergroup randomised trial was designed to investigate whether, in patients with operable non-small cell lung cancer of any stage, outcomes could be improved by giving platinum-based chemotherapy before surgery. Although surgery offers the best chance of cure for patients with non-small cell lung cancer (NSCLC), the overall 5-year survival rate is modest, and improvements are urgently needed.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |